)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jubilant Pharmova
Jubilant Pharmova (530019) investor relations material
Jubilant Pharmova Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary10 Aug, 2026
Executive summary
Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board and subjected to limited review by statutory auditors.
Both standalone and consolidated results were prepared in accordance with Ind AS and SEBI regulations.
Financial highlights
Consolidated revenue from operations for Q1 FY27 was ₹22,211 million, up from ₹18,789 million in Q1 FY26 and ₹22,722 million in Q4 FY26.
Consolidated profit for the period was ₹564 million, compared to ₹1,193 million in Q4 FY26 and ₹1,025 million in Q1 FY26.
Standalone revenue from operations for Q1 FY27 was ₹671 million, compared to ₹703 million in Q4 FY26 and ₹595 million in Q1 FY26.
Standalone profit for the period was ₹74 million, compared to ₹571 million in Q4 FY26 and ₹57 million in Q1 FY26.
Outlook and guidance
No explicit forward-looking guidance provided, but results were reviewed and approved by the Board, indicating ongoing operational focus.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jubilant Pharmova
- Record FY20 profitability came with COVID-19 disruption and deferred capex.530019
Q4 19/20 - Pharmaceuticals drove record revenue, while the IFC settlement weighed on reported profit.530019Q4 18/19
- Products growth offset weaker Services as FY11 results absorbed demerger and H1N1 comparisons.530019Q4 10/11
- Record FY17 results, injectables momentum and lower leverage offset significant operating risks.530019Q4 16/17
- EBITDA climbed 76% as pharma growth drove a strong FY16 earnings recovery.530019Q4 15/16
- Record FY18 growth, led by specialty pharma and ingredients, alongside debt reduction and Triad integration.530019Q4 17/18
- Flat revenue masked weaker earnings; radiopharma growth and FY16 recovery plans offered offsets.530019Q4 14/15
- Revenue grew 12%, while exceptional costs and sterile-compliance issues weighed on profit.530019Q4 13/14
- FY10 growth accelerated, led by pharma and life sciences, with debt reduced and expansion planned.530019Q4 09/10
- Revenue grew 25%, EBITDA 57%; exceptional charges cut reported PAT to ₹146 million.530019Q4 11/12
Next Jubilant Pharmova earnings date
Q2 26/2730 Oct, 2026
Jubilant Pharmova
Next Jubilant Pharmova earnings date
Q2 26/2730 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage